Table 2.
Risk-characteristics of patients undergoing TAVI over the years 2018–2020
| TAVI 2020 (n = 21,544) |
TAVI 2019 (n = 22,922) |
p-value 2020 vs. 2019 |
TAVI 2018 (n = 19,392) |
p-value 2020 vs. 2018 |
|
|---|---|---|---|---|---|
| Patient Characteristics influencing logES and AKL | |||||
| Age Median (IQR) | 81 (78–85) | 81 (78–85) | – | 81 (78–85) | – |
| Female gender | 49.6% | 48.6% | 0.34 | 49.4% | 0.26 |
| BMI < 18.5 kg/m2 | 1.4% | 1.5% | 0.44 | 1.4% | 0.78 |
| BMI > = 30 kg/m2 | 26.2% | 24.9% | < 0.001 | 24.8% | < 0.001 |
| Extracardiac arterial disease | 29.3% | 26.5% | < 0.001 | 26.2% | < 0.001 |
| COPD | 12.5% | 13.1% | 0.65 | 14.6% | < 0.001 |
| Endocarditis | 0.03% | 0.04% | 0.87 | 0.03% | 0.64 |
| Previous cardiac/aroticsurgery | 15.3% | 16.9% | 0.004 | 15.4% | 0.65 |
| Shock (< 48 h) | 3.4% | 2.4% | < 0.001 | 3.0% | 0.02 |
| Using of inotropes | 0.9% | 1.3% | < 0.001 | 1.6% | < 0.001 |
| Sinus rhythm at beginning of procedure | 66.8% | 65.4% | 0.002 | 65.1% | < 0.001 |
| LF-EF < 30% | 6.8% | 6.2% | 0.04 | 8.4% | < 0.001 |
| NYHA IV | 8.3% | 8.6% | 0.86 | 10.2% | < 0.001 |
| Recent MI (< 48 h) | 0.6% | 0.5% | 0.16 | 0.6% | 0.94 |
| CCS IV | 1.1% | 0.9% | 0.04 | 1.4% | 0.03 |
| Pulmonary hypertension | * | 46.8% | – | 46.5% | – |
| Emergency | 0.6% | 0.6% | 0.86 | 0.7% | 0.66 |
| sCR (mean; mg/dl)** | 1.18 | 1.17 | – | 1.19 | – |
| ASA-classification | < 0.001 | < 0.001 | |||
| 1 | 1.2% | 0.5% | < 0.001 | 0.3% | < 0.001 |
| 2 | 7.0% | 4.9% | < 0.001 | 5.1% | < 0.001 |
| 3 | 64.2% | 67.7% | < 0.001 | 69.3% | < 0.001 |
| 4 | 26.9% | 26.4% | 0.03 | 24.5% | < 0.001 |
| 5 | 0.7% | 0.6% | 0.15 | 0.9% | 0.05 |
*Information not available in 2020 (only mean PA pressure given)
**Standard deviation not available
IQR: interquartile range; COPD: chronic obstructive pulmonary disease; LV-EF: systolic left ventricular ejection fraction; NYHA: New York Heart Association; MI: myocardial infarction; CCS: Canadian Cardiovascular society; sCR: serum Creatinine; ASA: American Society of Anesthesiologists